Stories

The central comparison is not between vaping and doing nothing. It is between the risks of e-cigarettes and the far greater harms of continued smoking. For adults who smoke, the benefits of stopping combustible tobacco can substantially outweigh the uncertainties associated with switching to lower-risk nicotine products. Public health advice should make that hierarchy clear: quit smoking completely where possible, but do not let fear of imperfect alternatives keep people using cigarettes.

An internal memorandum can reveal more than a public statement. It shows how institutions frame risk, manage uncertainty and decide which voices are treated as credible before policy ever reaches the public. In nicotine regulation, that matters because language inside the system can shape whether harm reduction is seen as evidence, threat or inconvenience. Transparency is essential when decisions affect millions of adults who smoke.

Nicotine-free vapes show how easily regulation can drift from risk assessment into guilt by association. A product does not become equivalent to smoking simply because it sits near nicotine in the public debate. If rules are based on category suspicion rather than exposure, use and actual harm, they risk confusing consumers and weakening trust in public health. Regulation should be precise enough to distinguish what products contain, how they are used and what risks they genuinely present.

Sweden and the UK offer a useful comparison in what happens when smokers have access to credible alternatives. Oral nicotine products and other smoke-free options can change the trajectory of smoking rates when they are available, acceptable and regulated rather than pushed aside. The lesson is not that one product solves everything, but that people need more than warnings and willpower to leave cigarettes behind. Tobacco policy should study where smoking is falling fastest — and ask what made that possible.

The movement away from smoking is already happening in the data. A study showing exclusive vaping rising by 18.8% a year among US adults suggests that many people are not simply adding nicotine products, but replacing cigarettes with smoke-free alternatives. That distinction matters: full switching is where harm reduction has the greatest potential. Policy should pay attention to these behavioural shifts instead of treating all nicotine use as a failure.

When legal review moves slowly, the market does not wait politely. Delays in the FDA process can leave a void that illicit and unapproved products are quick to fill, while responsible pathways remain blocked or uncertain. That is not only a regulatory problem; it is a consumer protection problem. If safer nicotine products are to replace cigarettes, the legal system must be faster, clearer and capable of keeping people inside accountable markets.

Smoking is a major but often neglected driver of poor health among people with schizophrenia spectrum disorders. A 2026 scoping review found preliminary evidence that e-cigarette interventions may be feasible and acceptable in this group, with signs of smoking reduction, short-term abstinence and reduced exposure to tobacco-related carcinogens. The evidence is still limited, with only a small number of studies and important questions about long-term support and generalisability. But for a population where conventional cessation often performs poorly, harm reduction deserves serious clinical attention.

Regulatory meetings should be judged by whether they bring public health closer to real-world solutions. Responses to the FDA’s tobacco regulatory agenda show how wide the gap remains between precaution, evidence and the needs of adults who smoke. If the process treats lower-risk nicotine products mainly as a threat, it risks missing their potential role in reducing exposure to combustible tobacco. Better regulation starts with listening to evidence, consumers and unintended consequences — not only institutional caution.

Affordability can decide whether harm reduction is realistic or theoretical. A cross-country analysis of 55 countries found that heated tobacco products are often less affordable than cigarettes, especially in lower-income settings and among lower-income groups. That matters because price shapes behaviour: if lower-risk alternatives cost more than cigarettes, switching becomes harder for the people who may need it most. Tobacco policy should look beyond tax rates alone and consider the real consumer price of moving away from combustion.

Doctors are often the first trusted voice a smoker hears when trying to quit. If evidence supports vaping as a cessation aid, clinicians should be able to discuss it honestly rather than avoid the subject because of stigma. The goal is not to promote nicotine use, but to help people move away from combustible tobacco when other methods have not worked. Smoking cessation advice should reflect the full range of evidence-based options available to adults.